12 results
Primary Objective: to compare the atrial contractility by means of echocardiography between patients receiving flecainide and vernakalant i.v. after conversion to sinus rhythmSecondary Objective(s): 2a. To compare the conversion rate of AF between…
Sectie 2 van het CIP
Primary Objective: The aim of this study is to compare efficacy of antiarrhythmic drugs (sotalol or combination of flecainide and verapamil) and catheter ablation in reducing VPB/VT burden in patients with symptomatic idiopathic VPB/VTs.
The primary objective of this study is to evaluate whether the addition of epcoritamab to 6 cycles of standard R-CHOP followed by 2 cycles of epcoritamab (E + R-CHOP) can prolong progression-free survival (PFS) compared with 6 cycles of standard R-…
The study aims to evaluate a modified Anti-Platelet Therapy, when associated with low-dose rapamycin DES Firehawk in Acute Myocardial Infarction Patients treated with complete revascularization strategy.. The modified antiplatelet therapy consists…
Dose Escalation PhasePrimary - Evaluate the safety and tolerability of epcoritamab in combination with other agents Secondary- Characterize the PK properties of epcoritamab- To evaluate pharmacodynamic markers linked to efficacy and mechanism of…
Main objective Monotherapy Cohorts (R/R CLL):• Identify the RP2D and the MTD of epcoritamab• Evaluate the safety and tolerability of epcoritamabExpansion Monotherapy (R/R CLL [Arm 1] and RS [Arm 2A]):• Assess the preliminary efficacy of…
Compare the clinical efficacy of Epcoritamab to SOC (R-GemOx or BR)
The primary objectives of the study are to characterize the safety and toxicity profiles of epcoritamab when co-administered with anti-neoplastic agents in subjects with B-cell NHL and to determine the recommended dose for further investigation of…
To test the acute effect of beta-blockers vs flecainide on the reduction of PVCs in a pediatric population. Secondary objectives are to perform a prospective evaluation of the effect of PVCs on LV function, to test the effect of reduction of PVCs by…
This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with relapsed or refractory (R/R) FL. Adverse events and change in disease condition will be assessed.
Dose Escalation (GEN3009 for R/R B-cell NHL Including CLL/SLL):- Determine the MTD with and/or determine the RP2D of GEN3009- Evaluate safety and tolerability of GEN3009Expansion (GEN3009 for R/R, DLBCL, FL, and CLL Cohorts):-Evaluate (preliminary)…